What changed in this filing

/stocks — the workspaceLOADING

Item 1. Business

2024-07-25 compared with 2023-08-03 · 87 added, 125 removed, 310 unchanged (41% of the section changed)

5 unchanged sentences

in October 2012, the assets of Microsulis Medical Limited in January 2013, and Clinical Devices in August 2013.

These acquisitions added product lines

including ablation and NanoKnife systems, vascular access products, angiographic products and accessories, dialysis products, drainage products, thrombolytic products, embolization products and venous products.

These acquisitions added product lines including ablation and NanoKnife systems, vascular access products, angiographic products and accessories, dialysis products,

drainage products, thrombolytic products, embolization products and venous products.

In May 2012, the Company acquired Navilyst Medical's Fluid Management business, which the Company sold in May 2019 to Medline Industries, Inc.

pursuant to an asset purchase agreement.

In August 2018, the Company acquired the BioSentry product line from Surgical Specialties, LLC.

In August 2018, the Company acquired the BioSentry product line from Surgical Specialties, LLC, which the Company sold in June 2023 to Merit Medical Systems, Inc.

pursuant to an asset purchase agreement.

In September 2018, the Company acquired RadiaDyne, which included endorectal and vaginal balloons.

On October 2, 2019, the Company acquired Eximo Medical, Ltd., a pre-commercial stage medical device company and its proprietary 355nm laser atherectomy technology (now called Auryon), which treats Peripheral Artery Disease.

On December 17, 2019, the Company acquired the C3 Wave tip location asset from Medical Components Inc.

On July 27, 2021, AngioDynamics acquired the Camaro Support Catheter asset from QX Medical, LLC.

On December 17, 2019, the Company acquired the C3 Wave tip location asset from Medical Components Inc., which the Company sold in February 2024 to Spectrum Vascular pursuant to an asset purchase agreement.

On July 27, 2021, AngioDynamics acquired the Camaro Support Catheter asset from QX Medical, LLC and subsequently discontinued this product in the third quarter of fiscal year 2024.

AngioDynamics is publicly traded on the NASDAQ stock exchange under the symbol ANGO.

14 unchanged sentences

The AngioVac venous drainage cannula is a 22 French flat coil-reinforced cannula designed with a proprietary self-expanding nitinol reinforced funnel shaped distal tip.

The funnel shaped tip enhances venous drainage flow when the distal tip is exposed by retracting the sheath, helps prevent clogging of the cannula with commonly encountered undesirable intravascular material, and facilitates embolic removal of such extraneous material.

The funnel shaped tip enhances venous drainage flow when the distal tip

is exposed by retracting the sheath, helps prevent clogging of the cannula with commonly encountered undesirable intravascular material, and facilitates embolic removal of such extraneous material.

The AlphaVac System is an emergent mechanical aspiration device that eliminates the need for perfusionist support.

3 unchanged sentences

The handle is indicated as a vacuum source for the AlphaVac MMA system.

The AlphaVac F18 system is indicated for the treatment of pulmonary embolism and allows for the utilization in the non-surgical removal of thrombi or emboli from the venous vasculature, reducing thrombus burden and improving right ventricular function in patients with PE.

Thrombolytic Catheters

13 unchanged sentences

The energy delivery is hyperechoic and can be monitored under real-time ultrasound.

Peripheral Products (Core)

We offer a comprehensive portfolio for minimally invasive peripheral products.

Product categories include an extensive line of angiographic catheters and diagnostic and interventional guidewires, percutaneous drainage catheters and coaxial micro-introducer kits.

Angiographic Products and Accessories

Angiographic products and accessories are used during peripheral diagnostic and interventional procedures.

These products permit physicians to reach targeted locations to deliver contrast media for visualization purposes and therapeutic agents and devices, such as percutaneous transluminal angioplasty (PTA) balloons.

Angiographic products consist of angiographic catheters and guidewires.

Our angiographic catheter line includes the following brands, all with radiopaque tips to assure excellent visibility under fluoroscopy:

• Soft-Vu flush catheters are available in flush and selective varieties.

Flush catheters are used in procedures where a high flow of contrast is required for “big picture” diagnostics.

Anomalies discovered through a flush angiogram may require further investigation into a vessel of interest.

Soft-Vu selective catheters are used to gain access to smaller or more distal vessels and advance the catheter or wire into the diseased section.

• Accu-Vu sizing catheters feature radiopaque marker bands at the distal portion of the catheter to provide a highly accurate measurement of the patient’s anatomy.

This enables precise measurement for interventional devices such as stents.

• Mariner catheters have a hydrophilic coating that, when combined with water, reduces friction.

This makes insertion potentially easier and more comfortable for the patient, and can also be used for advancing through tortuous anatomy.

AngioDynamics guidewires include Nit-Vu (featuring a kink-resistant NiTi alloy core facilitating smooth navigation through tortuous vasculature and accurate wire control) and Polytetrafluoroethylene (PTFE) Coated diagnostic guidewires (fixed core and movable core).

AngioDynamics catheters and guidewires are available in more than 500 tip configurations and lengths.

Peripheral Products (Interventional Devices)

We offer a comprehensive portfolio of products for use during minimally invasive procedures.

Product categories include an extensive line of angiographic catheters, guidewires, drainage catheters and micropuncture kits.

Angiographic Catheters & Guidewires

Our extensive line of various angiographic catheter configurations are designed to allow physicians to navigate and reach targeted anatomical locations within a patient’s vasculature that are in need of angiographic diagnosis.

Typically run over a diagnostic guidewire, our angiographic catheters allow physicians to deliver contrast media to the desired location to determine the diagnosis and subsequent therapeutic modalities, as needed for the patient.

AngioDynamics offers three different angiographic catheter lines to meet physicians’ procedural needs.

All of our catheters feature our soft, atraumatic, super-radiopaque tip that is uniquely welded to our co-extruded nylon shaft, which provides excellent visibility under fluoroscopy and re-enforced tip stability.

• Soft-Vu Angiographic Catheters highlight the soft, atraumatic super-radiopaque and proprietary tip-to-shaft weld in a full offering of different tip shapes, lengths and french sized flush and selective catheters.

Flush catheters are used in procedures where a large volume of contrast is required to deliver a concentrated bolus of contrast quickly for visualization or larger anatomical locations, such as the aorta or for run-offs into lower extremities.

Selective catheters are typically used to gain access to more specific vasculature within the body to deliver smaller amounts of contrast.

Mariner Hydrophilic Catheters also feature a hydrophilic coating on the distal 20cm of the catheter that reduces friction during catheter advancement in the vasculature and allows for smooth navigation, as well as, optimum handling and control by the physician.

• Accu-Vu Sizing Catheters are our line of flush catheters that also feature highly visible radiopaque marker bands, which are heat embedded, along the catheter shaft, providing a smooth transition across the catheter shaft to ensure the marker bands will not separate from the shaft.

These radiopaque marker bands come in different patterns along the shaft and allow physicians, under fluoroscopy, to take measurements in different anatomical locations for the placement of stents, IVC filters or other devices.

The tight tolerances and consistent placement across the entire sizing pattern, within +/-1mm of accuracy, provide a highly accurate measurement to the physician.

AngioDynamics offers a line of diagnostic and interventional guidewires which are designed to aid in delivering diagnostic and/or therapeutic devices to the desired location.

• The ADx Peripheral Vascular Guidewire line is AngioDynamics diagnostic line of guidewires that is available in a multitude of fixed core wire configurations, including J-Tip and Bentson, in various lengths and ODs.

By utilizing a proprietary pre-coat process for the Polytetrafluoroethylene (PTFE) and upholding tight specifications, our ADx Guidewires offer high quality and performance for physicians.

• The NiT-Vu High Performance Micro Guidewires are our highly kink resistant nitinol shaft interventional wires that feature a highly visible radiopaque tungsten tip and lubricious coating.

The NiT-Vu wires are designed to reduce friction during wire advancement and also provides torque control, flexibility and kink resistance.

Drainage Products

Drainage products percutaneously drain abscesses and other fluid pockets.

An abscess is a tender inflamed mass that typically must be drained by a physician.

AngioDynamics offers two brands of drainage catheters for multi-purpose/general, nephrostomy and biliary drainage:

Total Abscession and Exodus.

Each offer features and benefits depending on case presentation and physician preferences.

Micro Access Kits

Our Micro Access kits provide interventional physicians a smaller introducer system for minimally-invasive procedures.

Our Micro Access product line provides physicians with the means to choose from the wide selection of configurations, including guidewire, needle and introducer options.

Two lines are available in stiff/standard, 10cm or 15cm and echogenic for visibility under ultrasound guidance:

Micro Introducer Kit and Ministick Max.

AngioDynamics offers the BioFlo catheter, the only catheter on the market with Endexo Technology, a material more resistant to thrombus accumulation, in vitro (based on platelet count).

Endexo Technology is a permanent and non-eluting polymer that is “blended” into the polyurethane from which the catheter is made.

It is present throughout the catheter, including the extraluminal, intraluminal and cut catheter surface of the tip.

Endexo Technology remains present for the life of the catheter.

The BioFlo catheter’s long-term durability and efficacy is intended to provide clinicians a high degree of safety and confidence in providing better patient care and improved patient outcomes.

BioFlo catheters are available across the Vascular Access family of products, including PICCs, midlines, ports and dialysis catheters.

Midline catheters are inserted via the same veins used for PICC placement in the middle third of the upper arm;

however, the midline catheter is advanced and placed so that the catheter tip is level or near the level of the axilla and distal to the shoulder.

Our Midline product is a BioFlo Midline Catheter which incorporates Endexo Technology and is an effective solution to preserving a patient’s peripheral access.

It provides a cost-effective alternative to multiple IV site rotations for patients who need short-term venous access.

A peripherally inserted central catheter, or PICC, is a long thin catheter that is inserted into a peripheral vein, typically in the upper arm, and advanced until the catheter tip terminates in a large vein in the chest near the heart to obtain intravenous access.

PICCs can typically be used for prolonged periods of time and provide an alternative to central venous catheters.

Our PICC product offerings include:

• BioFlo PICC :

Our BioFlo PICC line is the only power injectable PICC available that incorporates Endexo Technology into the manufacturing and design of the catheter.

Advanced features such as large lumen diameters allow the BioFlo PICC to deliver the power injection flow rates required for contrast-enhanced Computed Tomography (CT) scans compatible with up to 325 psi CT injections.

• Xcela PICC :

The Xcela PICC line is designed to provide a high degree of safety, ease and confidence in patient care.

Advanced features such as large lumen diameters allow the Xcela PICC to deliver the power injection flow rates required for contrast-enhanced CTs compatible with up to 325 psi CT injections.

• PASV Valve Technology:

The PASV Valve Technology is available in both BioFlo and Xcela lines and is designed to automatically resist backflow and reduce blood reflux that could lead to catheter-related complications.

C3 Wave PICC tip location system

The C3 Wave system is our innovative, wireless, app-based ECG system which eliminates the need for a confirmatory chest x-ray of PICC tip placement, allowing greater patient access to the Company’s proprietary BioFlo PICCs.

To aid physicians in percutaneous drainage procedures, AngioDynamics offers two different Drainage Catheter lines:

Total Abscession Drainage Catheters and Exodus Drainage Catheters.

Each line is available in a Multipurpose/General and Biliary configuration, while Total Abscession also offers a Nephrostomy option.

Both lines offer options with a radiopaque marker band at the distal tip to aid in placement.

• The Total Abscession Drainage Catheter line offers a soft, kink resistant shaft that features the lubricious Blue Silk Finish for easier insertion and pushability, while providing the optimal patient comfort.

The unique Vault Locking Mechanism securely fixes the pigtail and prevents tampering or accidental removal.

• The Exodus Drainage line features an integrated polymer blend extruded shaft with external catheter markings, and GLYCE Hydrophilic Coating on the distal 20cm of the catheter shaft.

The unique Sure-Twist hub provides audible and tactile feedback when locked, without the need for a separate tool.

Micropuncture Kits

AngioDynamics offers physicians two micropuncture kit lines that are designed to start each procedure with ease and efficiency:

Mini Stick MAX Coaxial Microintroducer Kits and Micro-Introducer Kits.

Each kit features a coaxial design with a 4F or 5F sheath introducer and stiff or standard dilator, along with a 21G needle and various 0.018” access wire configurations.

• Mini Stick MAX Coaxial Introducer kits contain a unique containment clip that keeps all the unique components of the kit together and organize.

The kit options include our AngioDynamics proprietary coaxial introducer with smooth transition at the tip, translucent 21G needle with bevel indicator and 0.018” access wire available in three different wire material configurations.

• The Micro-Introducer Kits offer a variety of configurations that include aid in simplifying set up and gaining vascular access.

Ports are implantable devices utilized for the central venous administration of a variety of medical therapies and for blood sampling and diagnostic purposes.

3 unchanged sentences

Our port products and accessories include:

• BioFlo Port :

Our BioFlo Port was the first port available featuring a catheter with Endexo Technology.

Advanced features of the BioFlo Port include multiple profile and catheter options, a large septum area for ease of access and the ability to administer contrast through a CT injection for purposes of imaging.

• SmartPort, SmartPort+, SmartPort Plastic :

The SmartPort power-injectable port with Vortex technology offers the ability for a clinician to access a vein for both the delivery of medications or fluids and for administering power-

injected contrast to perform a CT scan.

The SmartPort power-injectable port with Vortex technology offers the ability for a clinician to access a vein for both the delivery of medications or fluids and for administering power-injected contrast to perform a CT scan.

The ability to access a port for power-injected contrast studies eliminates the need for additional needle sticks in the patient’s arm and wrist veins.

Once implanted, repeated access to the bloodstream can be accomplished with greater ease and less discomfort.

Our SmartPort port line is available in standard, mini and low-profiles to accommodate more patient anatomies.

Our SmartPort port line is available in standard, mini and low-profile to accommodate more patient anatomies.

The SmartPort+ port line combines Vortex technology with BioFlo catheters.

In addition to the three titanium port body sizes, there is a plastic port body.

• BioFlo Port :

Our BioFlo Port was the first port available featuring a catheter with Endexo Technology.

Advanced features of the BioFlo Port include multiple profile and catheter options, a large septum area for ease of access, PASV and non-PASV valve technology and the ability to administer contrast through a CT injection for purposes of imaging.

• Xcela Plus :

The Xcela Plus Port product family is Power-Injectable and part of a complete portfolio of vascular access products, and is fully compatible with the LifeGuard Safety Infusion product family.

It has easily identifiable critical information radiopaque “CT” lettering which helps to confirm if port is power-injectable or flipped.

The Xcela Plus port family is available in single lumen standard size in either a non-valved or valved configuration.

Port Technologies

AngioDynamics offers the BioFlo catheter, the only catheter on the market with Endexo Technology, a material more resistant to thrombus accumulation, in vitro (based on platelet count).

Endexo Technology is a permanent and non-eluting polymer that is “blended” into the polyurethane from which the catheter is made.

It is present throughout the catheter, including the extraluminal, intraluminal and cut catheter surface of the tip.

Endexo Technology remains present for the life of the catheter.

The BioFlo catheter’s long-term durability and efficacy is intended to provide clinicians a high degree of safety and confidence in providing better patient care and improved patient outcomes

Our Vortex port technology line of ports features a clear-flow port technology that, we believe, revolutionized port design.

3 unchanged sentences

The PASV Valve Technology is designed to automatically resist backflow and reduce blood reflux that could lead to catheter-related complications.

Dialysis Products

We market an extensive line of dialysis products that provide short and long-term vascular access for dialysis patients.

Dialysis, or cleaning of the blood, is necessary in conditions such as acute renal failure, chronic renal failure and end-stage renal disease (ESRD).

We currently offer a variety of dialysis catheters, including:

• BioFlo DuraMax :

Our BioFlo DuraMax dialysis catheter is the only dialysis catheter with Endexo Technology.

Advanced features of the BioFlo DuraMax dialysis catheter include large inner diameter lumens designed for long term patency, a proprietary guidewire lumen to facilitate catheter exchanges and Curved Tip Technology that allows the catheter to self-center in the Superior Vena Cava (SVC).

The DuraMax catheter is a stepped-tip catheter designed to improve ease of use, dialysis efficiency and overall patient outcomes.

In addition, AngioDynamics also offers other renal therapies, including our DuraFlow Chronic Hemodialysis Catheter, Acute Dialysis Catheter, EVENMORE Chronic Hemodialysis Catheter, EMBOSAFE Valved Splitable Sheath Dilator and Perchik Button Suture Retention Device.

Venous Insufficiency

20 unchanged sentences

The Solero MTA System is not intended for cardiac use.

Radiofrequency Ablation

StarBurst Radiofrequency Ablation Devices

Radiofrequency Ablation (RFA) products use radiofrequency energy to provide a minimally invasive approach to ablating solid cancerous or benign tumors.

Our StarBurst Radiofrequency Ablation devices deliver radiofrequency energy to raise the temperature of cells above 45-50°C, causing cellular death.

The physician inserts the disposable needle electrode device into the targeted body tissue, typically under ultrasound, CT or Magnetic Resonance Imaging (MRI) guidance.

During the procedure, our system automatically adjusts the amount of energy delivered in order to maintain the temperature necessary to ablate the targeted tissue.

For a typical 5 cm ablation using our StarBurst Xli-enhanced disposable device, the ablation process takes approximately ten (10) minutes.

The RFA system consists of a radiofrequency generator and a family of disposable devices.

In addition to thermal ablation systems and the NanoKnife Ablation System, AngioDynamics also offers Habib 4X Surgical Resection devices that are used in minimally invasive laparoscopic surgery procedures in surgical specialties such as Hepato-Biliary, GI, Surgical Oncology, Transplant Surgery and Urology (Partial Nephrectomy Resections).

It is clinically indicated to assist in coagulation of tissue during intraoperative and laparoscopic procedures.

BioSentry Tract Sealant System

The BioSentry Tract Sealant System deploys a self-expanding hydrogel plug into the pleural space following a percutaneous lung biopsy, creating an airtight seal that closes the pleural puncture.

Depth markings provide accurate and consistent placement based on CT-guided measurements, while the depth adjustment wheel and locking mechanisms ensure proper plug deployment.

The hydrogel plug is made from a synthetic tissue-friendly polymer that fully reabsorbs into the body and the coaxial adapter mates with a coaxial needle to ensure a proper fit and delivery of the plug.

The BioSentry Tract Sealant System is indicated for sealing pleural punctures to significantly reduce the risk of pneumothoraxes (air leaks) associated with percutaneous, transthoracic needle lung biopsies and to provide accuracy in marking a biopsy location for visualization during surgical resection.

IsoLoc Endorectal Balloon

57 unchanged sentences

The Company also relies on third party manufacturers for the manufacturing of certain products.

During the third quarter of fiscal year 2024, AngioDynamics announced the restructuring of its manufacturing footprint and a plan to shift to a fully outsourced model by the third quarter of fiscal year 2026.

We have historically kept sufficient inventory on hand to ship product within 24-48 hours of order receipt to meet customer demand.

In fiscal year 2023, the Company's ability to manufacture products, the reliability of our supply chain, labor shortages, backlog and inflation (including the cost and availability of raw materials, direct labor and shipping) have impacted our business and resulted in a backlog of $2.7 million at the end of the fourth quarter.

In fiscal year 2024, the Company's ability to manufacture products, the reliability of our supply chain, labor shortages, backlog and inflation (including the cost and availability of raw materials, direct labor and shipping) have impacted our business and resulted in a backlog of $1.3 million at the end of the fourth quarter down $1.4 million from the fourth quarter of fiscal year 2023.

We continue to focus on meeting the demand for our product and working towards standard inventory and backlog levels in fiscal year 2025.

21 unchanged sentences

Before a new medical device can be introduced into the market, a manufacturer generally must obtain marketing clearance or approval from the FDA through either a 510(k) submission (a premarket notification) or a premarket approval application (PMA).

The 510(k) clearance procedure is available only if a manufacturer can establish that its device is “substantially equivalent” in intended use and in safety and effectiveness to a “predicate device,” which is (i) a device that has been cleared through the 510(k) clearance process;

(ii) a device that was legally marketed prior to May 28, 1976 (preamendments device);

(iii) a device that was originally on the U.S.

through the 510(k) clearance process;

(ii) a device that was legally marketed prior to May 28, 1976 (preamendment device);

or (iii) a device that was originally on the U.S.

market as a Class III device (Premarket approval) and later downclassified to Class II or I.

(iv) or a 510(k) exempt device.

After a device receives 510(k) clearance, any modification that could significantly affect

its safety or effectiveness, or that would constitute a major change in its intended use, requires a new 510(k) clearance.

After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, requires a new 510(k) clearance.

The 510(k) clearance procedure including questions and responses may take up to 12 months.

35 unchanged sentences

In order to distribute and sell products into the European Union as well as a number of other countries including many Central European Free Trade Agreement participants, Scandinavian, and Middle Eastern countries, a CE Mark is required.

products must be compliant with the Medical Device Regulation ("MDR") as of May 2021 and previously CE Marked products must become compliant when their certification expires, with a transition period ending December 2027 for higher classification devices, or December 2028 for lower classification devices.

New products must be compliant with the Medical Device Regulation ("MDR") as of May 2021 and previously CE Marked products must become compliant when their certification expires, with a transition period ending December 2027 for higher classification devices, or December 2028 for lower classification devices.

Products with an expiring certification must be in distribution before certification expiration dates to continue to be sold.

29 unchanged sentences

International

The delivery of our devices in any market is subject to evolving regulation by the EU Medical Device Regulations, notified bodies and comparable nation-specific bodies responsible for reimbursement and regulation of health care items and services.

The delivery of our devices in any EU member country is subject to evolving regulation by the EU Medical Device Regulations, notified bodies and comparable nation-specific bodies whether part of the EU or not, responsible for reimbursement and regulation of health care items and services.

Our success in international markets will depend largely upon the availability of reimbursement from the national public health payers as well as private, third party payors, through which healthcare providers are paid in those markets.

1 unchanged sentence

The main types of healthcare payment systems are government sponsored healthcare and private insurance.

Reimbursement approval must be obtained individually in each country in which our products are marketed.

Outside the U.S., we maintain a healthcare economics team that works directly with providers, our distributors and health systems to obtain reimbursement approval in the countries in which they will use or sell our products.

Reimbursement

approval must be obtained individually in each country in which our products are marketed.

Members of our healthcare economics team work directly with providers, our distributors and health systems to obtain reimbursement approval in the countries in which they will use or sell our products.

There can be no assurance that reimbursement approvals will be received.

19 unchanged sentences

We communicate frequently and transparently with our employees through a variety of communication methods, including video and written communications, town hall meetings and our company intranet.

As a result of the COVID-19 pandemic, we also further strengthened our communication platforms.

Our employee communications during the pandemic have kept our employees informed on critical priorities, important actions being taken by management in response to the pandemic and continued efforts to protect employee health, safety and well-being.

Executive Officers of the Company

3 unchanged sentences

Trowbridge 50 Executive Vice President and Chief Financial Officer

Campbell 52 Senior Vice President and General Manager, Vascular Access and Oncology

Scott Centea 45 Senior Vice President and General Manager, Endovascular Therapies

Helsel 59 Senior Vice President, Global Operations and Research and Development

Laura Piccinini 53 Senior Vice President and General Manager, International

Campbell 53 Senior Vice President and General Manager, Global Oncology and Vascular Access

Laura Piccinini 54 Senior Vice President and General Manager, Endovascular Therapies and International

Nighan 55 Senior Vice President, Global Supply Chain, Quality and Regulatory Affairs

Clemmer became our President and Chief Executive Officer (CEO) in April 2016.

5 unchanged sentences

Clemmer served as Group President at Kendall Healthcare (which was acquired by Tyco International in 1994), where he managed the U.S.

business across five divisions and built the strategic plan for the medical supplies segment before Covidien was spun off from Tyco.

business across five divisions and built the strategic plan for the medical supplies segment before Covidien was spun off

Clemmer began his career at Sage Products, Inc.

Clemmer currently serves on the Board of Directors for

AngioDynamics and previously served on the Board of Directors for Lantheus Medical Imaging.

Clemmer currently serves on the Board of Directors for AngioDynamics and previously served on the Board of Directors for Lantheus Medical Imaging.

Clemmer is a graduate of the Massachusetts College of Liberal Arts, where he served as interim president from August 2015 until March 2016.

3 unchanged sentences

In addition to serving as the Company’s CFO and managing the finance functions, Mr.

Trowbridge also managed the Legal function on an interim basis until January 30, 2021.

Trowbridge also manages the Legal function.

Prior to AngioDynamics, Mr.

6 unchanged sentences

In his role, Mr.

Campbell oversees research and development and global commercialization of the Global Business Unit’s portfolio.

Campbell oversees global commercialization of the Global Business Unit’s portfolio.

Campbell joined AngioDynamics from Medtronic where he served as the Vice President of Marketing for the Patient Care and Safety business after serving as the Vice President of Marketing for the SharpSafety business at Covidien (Medtronic).

2 unchanged sentences

Campbell received a Bachelor of Arts from the University of Kentucky.

Scott Centea joined AngioDynamics in 2005 as a sales representative serving the Carolinas.

During his tenure, he has served in a variety of positions with increased responsibility including Vice President of Corporate Accounts where he was in charge of leading a team of individuals to execute Health System Purchasing Contracts.

From there Mr.

Centea assumed the role of Vice President of Marketing for Endovascular Therapies, before being promoted into his most recent and current role as Senior Vice President/General Manager of Endovascular Therapies and Peripheral Artery Disease.

Centea currently holds board positions with the American Venous Forum (AVF) and the Capital District American Heart Association.

Centea holds a Bachelor of Arts in Communications from Newberry College.

Helsel currently serves as Senior Vice President of Global Operations and Research and Development and has been with AngioDynamics since December 2017.

Prior to joining AngioDynamics he was Senior Vice President, Global Supply Chain, at Hill-Rom Holdings for almost three years.

Before that, Mr.

Helsel worked at Haemonetics for three years where he served as Executive Vice President for Global Manufacturing and also spent almost nineteen years in various positions with increasing responsibility at Covidien, including Vice President of Operations for the Surgical Solutions Division and Medical Supplies Division.

An expert in Lean and Six Sigma, Mr.

Helsel also served as Global Director of Operational Excellence, supporting sixty-three manufacturing facilities.

Helsel holds a Bachelor of Science in Mechanical Engineering from LeTourneau University.

Laura Piccinini joined AngioDynamics as Senior Vice President and General Manager for International in June 2021.

Laura Piccinini was appointed Senior Vice President and Global Manager for Endovascular Therapies and International in January 2024, after serving as Senior Vice President and General Manager for International since joining AngioDynamics in June 2021.

Piccinini brings more than 25 years of experience in leadership roles in the medical device industry, with an extensive background in the field of respiratory and surgical care.

4 unchanged sentences

Piccinini is a graduate of the Parma University of Medicine, where she received a nursing degree with specializations in ICU, Anesthesia, and First Aid as a Helicopter Flight Coordinator.

Nighan was appointed Senior Vice President, Global Supply Chain, Quality and Regulatory Affairs in March 2024, after serving as Senior Vice President of Quality and Regulatory Affairs since joining AngioDynamics in April 2017.

Before joining AngioDynamics, Mr.

Nighan was a quality and regulatory consultant to clients in FDA-regulated industries, specializing in execution and management of quality systems implementation and remediation.

Previously, Mr.

Nighan served as the Executive Vice President of Global Clinical, Quality Affairs and Regulatory Affairs at Haemonetics Corporation, Vice President of Quality/Regulatory/Clinical/Technical Services at St.

Jude Medical’s Atrial Fibrillation Division, and Corporate Vice President of Quality/Compliance at Tyco Healthcare/Covidien (Medtronic).

Nighan earned a Bachelor and Master of Science in Nursing from Northeastern University’s Bouvé College of Health Sciences.

AVAILABLE INFORMATION

7 unchanged sentences

Accordingly, investors should monitor our website, in addition to following our press releases, SEC filings and public conference calls and webcasts.

We use these channels as well

as social media and blogs to communicate with the public about our company, our services and other issues.

We use these channels as well as social media and blogs to communicate with the public about our company, our services and other issues.

It is possible that the information we post on social media and blogs could be deemed to be material information.

4 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 1. Business